PPD, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David S. Simmons
- Full Time Employees
- 30,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 929 North Front Street Wilmington NC United States of America 28401-3331
- IPO Date
- Feb 6, 2020
- CIK
- 0001793294
- Website
- ppd.com
- Similar Companies
- Business
- PPD, Inc. PPD, Inc. (Nasdaq: PPD), the clinical research business of Thermo Fisher Scientific Inc., operates as a leading global contract research organization (CRO) providing comprehensive drug development, laboratory, and lifecycle management services to pharmaceutical, biotechnology, medical device, academic, and government customers worldwide; core offerings encompass clinical development services including early development, Phase I-IV trial management, accelerated enrollment, peri- and post-approval support, and medical communications, alongside advanced laboratory services such as bioanalytical testing, biomarkers, central labs, GMP manufacturing, and vaccine sciences across more than 20 therapeutic areas like oncology, immunology, infectious diseases, cardiology, neurology, cell and gene therapy, gastroenterology, dermatology, nephrology, pediatrics, and respiratory conditions. Headquartered in Wilmington, North Carolina, and founded in 1985, the company maintains a global presence with operations in over 38 countries, leveraging innovative technologies, patient-centered strategies, data analytics, and a network of laboratories to accelerate therapies from discovery through regulatory approval and market access. Recent developments include the 2023 acquisition of CorEvitas to enhance real-world evidence capabilities, multiple expansions of clinical research laboratories in Kentucky, Wisconsin, and Europe as of 2024-2025, the launch of new CorEvitas clinical registries for conditions such as Myasthenia Gravis, Systemic Lupus Erythematosus, and Adolescent Alopecia Areata in 2025, a strategic R&D partnership with AstraZeneca BioVentureHub and collaboration with OpenAI to accelerate life science breakthroughs in October 2025, introduction of an innovative carbon calculator for greener clinical trials, and extensions of contracts with the U.S. National Institutes of Health for HIV therapies and other programs.
Thermo Fisher Scientific's PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden
Thermo Fisher Scientific's PPD Clinical Research Business Collaborates with HealthVerity to Expand Real-World Data Capabilities
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer's Disease Registry to Advance Real-World Evidence in Neurodegenerative Care
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
Reunion Neuroscience Announces Last Patient Dosed in RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
FINAL PPD DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds PDD Holdings Inc. f/k/a Pinduoduo Inc. Investors to Join the Class Action Lawsuit!
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results
Thermo Fisher Scientific's PPD Clinical Research Business Earns TOPRA Award for Regulatory Affairs Excellence in Supporting Novavax's COVID-19 Vaccine Approval
Saama Appoints Scott Rogers as Company's Chief Financial Officer
Thermo Fisher Scientific Completes Acquisition of PPD, Inc.
PPD Named to ‘Best Workplaces in Greater China’ for Second Consecutive Year
PPD Named to ‘Best Workplaces in Greater China' for Second Consecutive Year
PPD 连续第二年荣膺2021年度“大中华区最佳职场TM”称号
PPD 連續第二年榮膺2021年度「大中華區最佳職場TM」稱號